Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Jim O'Neill Optimistic His AMR Review Won't Run Into The Sand

This article was originally published in Scrip

Executive Summary

Jim O'Neill says he spends sleepless nights worrying whether his Review of Antimicrobial Resistance (AMR) will run out of steam once completed in two months' time – but he's encouraged by growing evidence world leaders and the pharma industry are seriously embracing the theme and will soon make lasting commitments to effectively combat antibiotic resistance.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst